IL-13 inhibitor

0 marketed 1 in Phase 3 1 in Phase 2

This page covers all IL-13 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-13.

Targets

Phase 3 pipeline (1)

Tralokinumab + TCS · LEO Pharma · Dermatology
Tralokinumab is an IL-13 inhibitor, and when combined with topical corticosteroids (TCS), it targets the underlying inflammatory pathways in atopic dermatitis.

Phase 2 pipeline (1)

AER 001 · Aerovance, Inc. · Respiratory
AER 001 is an investigational monoclonal antibody targeting IL-13.